Citation

Keil JM, Rafn GR, Turan IM, Aljohani MA, Sahebjam-Atabaki R, Sun XL. J. Med. Chem. 2022; 65(20): 13574-13593.

Copyright

(Copyright © 2022, American Chemical Society)

DOI

10.1021/acs.jmedchem.2c01258

PMID

36252951

PMCID

PMC9620260

Abstract

Sialidases, or neuraminidases, are enzymes that catalyze the hydrolysis of sialic acid (Sia)-containing molecules, mostly removal of the terminal Sia (desialylation). By desialylation, sialidase can modulate the functionality of the target compound and is thus often involved in biological pathways. Inhibition of sialidases with inhibitors is an important approach for understanding sialidase function and the underlying mechanisms and could serve as a therapeutic approach as well. Transition-state analogues, such as anti-influenza drugs oseltamivir and zanamivir, are major sialidase inhibitors. In addition, difluoro-sialic acids were developed as mechanism-based sialidase inhibitors. Further, fluorinated quinone methide-based suicide substrates were reported. Sialidase product analogue inhibitors were also explored. Finally, natural products have shown competitive inhibiton against viral, bacterial, and human sialidases. This Perspective describes sialidase inhibitors with different mechanisms and their activities and future potential, which include transition-state analogue inhibitors, mechanism-based inhibitors, suicide substrate inhibitors, product analogue inhibitors, and natural product inhibitors.

Language: en

Keywords

Humans; *Biological Products; *Neuraminidase/metabolism; Antiviral Agents/pharmacology; Enzyme Inhibitors/pharmacology/chemistry; N-Acetylneuraminic Acid; Oseltamivir/pharmacology; Sialic Acids/chemistry; Zanamivir